New cocktail of drugs shows promise for Tough-to-Treat throat cancer
NCT ID NCT06059261
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding an immunotherapy drug (envafolimab) and a blood-vessel blocker (endostatin) to standard chemoradiotherapy can improve outcomes for 30 people with locally advanced nasopharyngeal carcinoma. The main goal is to see how many patients have a complete disappearance of their tumors after the initial treatment phase. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
envafolimab (an immunotherapy drug) combined with chemotherapy (cisplatin, gemcitabine) and recombinant human endostatin (a drug that blocks blood vessel growth to tumors)
What this could lead to
If successful, this combination could offer a more effective treatment option for people with advanced nasopharyngeal cancer, potentially improving tumor shrinkage and delaying progression.
What could go wrong
This is a small, early-phase (phase II) study with only 30 participants, so results may not apply to everyone. The combination of drugs may cause significant side effects, and it is not yet known if it works better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, 400030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••